Osteocalcin, osteopontin and RUNX2 expression in patients with arteriosclerosis

Ukkat,Jörg; Hoang-Vu,Cuong; Trojanowicz,Bogusz; Rebelo,Artur

doi:10.3892/wasj.2021.103

Osteocalcin, osteopontin and RUNX2 expression in patients with arteriosclerosis

Authors:
- Jörg Ukkat
- Cuong Hoang-Vu
- Bogusz Trojanowicz
- Artur Rebelo
View Affiliations

Affiliations: Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany
Published online on: April 21, 2021 https://doi.org/10.3892/wasj.2021.103
Article Number: 32
Copyright: © Ukkat et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Knowledge of the role of the skeleton as an endocrine organ has increase over the past years. The role of calcification in arteriosclerotic disease has also been a matter of investigation. Since there is a clear association between the levels of osteocalcin (OC), osteopontin (OPN) and Runt‑related transcription factor 2 (RUNX2) and the development of arteriosclerotic vascular disease, the present study examined the expression of OC, OPN and RUNX2 in vascular tissue and their possible employment as diagnostic markers for cardiovascular disease. For this purpose, 13 vessel tissues, including tissues from six patients without arteriosclerotic disease (PAD‑) and 7 patients with arteriosclerotic disease (PAD+) were obtained by surgical resection. Immunohistochemistry and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis were performed. The results revealed that tissues representing PAD+ exhibited a noticeably stronger protein expression of OC, OPN and RUNX2 as compared with the corresponding PAD‑ tissues. The transcript levels of OPN and RUNX2 were associated with protein expression and were significantly elevated in PAD+ (OPN, P<0.05; RUNX2, P<0.01). The expression of OC in PAD+ was noticeably increased as compared with PAD‑ (P=0.067). On the whole, the present study demonstrates that the expression of OC, OPN and RUNX2 in arterial tissue is strongly associated with symptomatic arteriosclerotic disease. Further investigations are required however, to prove the tge clinical significance of OC, OPN and RUNX2 as potential biomarkers for atherosclerotic disease.

View Figures

View References

1	Ferron M and Lacombe J: Regulation of energy metabolism by the skeleton: Osteocalcin and beyond. Arch Biochem Biophys. 561:137–146. 2014.PubMed/NCBI View Article : Google Scholar
2	Fishbein GA and Fishbein MC: Arteriosclerosis: Rethinking the current classification. Arch Pathol Lab Med. 133:1309–1316. 2009.PubMed/NCBI View Article : Google Scholar
3	Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW and Kroon AA: Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vasc Health Risk Manag. 5:185–197. 2009.PubMed/NCBI View Article : Google Scholar
4	Shobeiri N, Adams MA and Holden RM: Vascular calcification in animal models of CKD: A review. Am J Nephrol. 31:471–481. 2010.PubMed/NCBI View Article : Google Scholar
5	World Health Organization: Cardiovascular Diseases. https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1. Accessed December 2, 2020.
6	Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R and Taubert K: Coronary artery calcification: Pathophysiology, epidemiology, imaging methods, and clinical applications. Circulation. 94:1175–1192. 1996.PubMed/NCBI View Article : Google Scholar
7	Zoch ML, Clemens TL and Riddle RC: New insights into the biology of osteocalcin. Bone. 82:42–49. 2016.PubMed/NCBI View Article : Google Scholar
8	Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, et al: Endocrine regulation of energy metabolism by the skeleton. Cell. 130:456–469. 2007.PubMed/NCBI View Article : Google Scholar
9	Sheng L, Cao W, Cha B, Chen Z, Wang F and Liu J: Serum osteocalcin level and its association with carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 12(22)2013.PubMed/NCBI View Article : Google Scholar
10	Tacey A, Qaradakhi T, Brennan-Speranza T, Hayes A, Zulli A and Levinger I: Potential role for osteocalcin in the development of atherosclerosis and blood vessel disease. Nutrients. 10(E1426)2018.PubMed/NCBI View Article : Google Scholar
11	Millar SA, Patel H, Anderson SI, England TJ and O'Sullivan SE: Osteocalcin, vascular calcification, and atherosclerosis: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 8(183)2017.PubMed/NCBI View Article : Google Scholar
12	Lund SA, Giachelli CM and Scatena M: The role of osteopontin in inflammatory processes. J Cell Commun Signal. 3:311–322. 2009.PubMed/NCBI View Article : Google Scholar
13	Lok ZSY and Lyle AN: Osteopontin in vascular disease. Arterioscler Thromb Vasc Biol. 39:613–622. 2019.PubMed/NCBI View Article : Google Scholar
14	Moe SM, Duan D, Doehle BP, O'Neill KD and Chen NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 63:1003–1011. 2003.PubMed/NCBI View Article : Google Scholar
15	Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL and Shanahan CM: Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 23:489–494. 2003.PubMed/NCBI View Article : Google Scholar
16	Li Y, Wang W, Chao Y, Zhang F and Wang C: CTRP13 attenuates vascular calcification by regulating Runx2. FASEB J. 33:9627–9637. 2019.PubMed/NCBI View Article : Google Scholar
17	Zhu L, Zhang N, Yan R, Yang W, Cong G, Yan N, Ma W, Hou J, Yang L and Jia S: Hyperhomocysteinemia induces vascular calcification by activating the transcription factor RUNX2 via Krüppel-like factor 4 up-regulation in mice. J Biol Chem. 294:19465–19474. 2019.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Rasmussen R: Quantification on the Light Cycler. In: Rapid Cycle Real-Time PCR. Meuer S, Wittwer C and Nakagawara KI (eds). Springer, Heidelberg, pp21-34 2001.
20	Mizokami A, Kawakubo-Yasukochi T and Hirata M: Osteocalcin and its endocrine functions. Biochem Pharmacol. 132:1–8. 2017.PubMed/NCBI View Article : Google Scholar
21	Li J, Zhang H, Yang C, Li Y and Dai Z: An overview of osteocalcin progress. J Bone Miner Metab. 34:367–379. 2016.PubMed/NCBI View Article : Google Scholar
22	Kord-Varkaneh H, Djafarian K, Khorshidi M and Shab-Bidar S: Association between serum osteocalcin and body mass index: A systematic review and meta-analysis. Endocrine. 58:24–32. 2017.PubMed/NCBI View Article : Google Scholar
23	Pal SN, Rush C, Parr A, Van Campenhout A and Golledge J: Osteocalcin positive mononuclear cells are associated with the severity of aortic calcification. Atherosclerosis. 210:88–93. 2010.PubMed/NCBI View Article : Google Scholar
24	Yuen CY, Wong SL, Lau CW, Tsang SY, Xu A, Zhu Z, Ng CF, Yao X, Kong SK, Lee HK, et al: From skeleton to cytoskeleton: Osteocalcin transforms vascular fibroblasts to myofibroblasts via angiotensin II and Toll-like receptor 4. Circ Res. 111:e55–e66. 2012.PubMed/NCBI View Article : Google Scholar
25	Ramirez-Sandoval JC, Casanova I, Villar A, Gomez FE, Cruz C and Correa-Rotter R: Biomarkers associated with vascular calcification in peritoneal dialysis. Perit Dial Int. 36:262–268. 2016.PubMed/NCBI View Article : Google Scholar
26	Schinzari F, Tesauro M, Bertoli A, Valentini A, Veneziani A, Campia U and Cardillo C: Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: Influence of oral hypoglycemic agents. Am J Physiol Endocrinol Metab. 317:E658–E666. 2019.PubMed/NCBI View Article : Google Scholar
27	Icer MA and Gezmen-Karadag M: The multiple functions and mechanisms of osteopontin. Clin Biochem. 59:17–24. 2018.PubMed/NCBI View Article : Google Scholar
28	Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G and Giachelli CM: Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: Evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 196:1047–1055. 2002.PubMed/NCBI View Article : Google Scholar
29	Scatena M, Liaw L and Giachelli CM: Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 27:2302–2309. 2007.PubMed/NCBI View Article : Google Scholar
30	Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, Dear AE, Palmer LJ and Norman PE: Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 27:655–660. 2007.PubMed/NCBI View Article : Google Scholar
31	Berezin AE and Kremzer AA: Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis. 229:475–481. 2013.PubMed/NCBI View Article : Google Scholar
32	Cho HJ, Cho HJ and Kim HS: Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 11:206–213. 2009.PubMed/NCBI View Article : Google Scholar
33	Lino M, Wan MH, Rocca AS, Ngai D, Shobeiri N, Hou G, Ge C, Franceschi RT and Bendeck MP: Diabetic vascular calcification mediated by the collagen receptor discoidin domain receptor 1 via the phosphoinositide 3-kinase/Akt/Runt-related transcription factor 2 signaling axis. Arterioscler Thromb Vasc Biol. 38:1878–1889. 2018.PubMed/NCBI View Article : Google Scholar
34	Tanaka T, Sato H, Doi H, Yoshida CA, Shimizu T, Matsui H, Yamazaki M, Akiyama H, Kawai-Kowase K, Iso T, et al: Runx2 represses myocardin-mediated differentiation and facilitates osteogenic conversion of vascular smooth muscle cells. Mol Cell Biol. 28:1147–1160. 2008.PubMed/NCBI View Article : Google Scholar
35	Al-Huseini I, Ashida N and Kimura T: Deletion of IκB-Kinase β in smooth muscle cells induces vascular calcification through β-catenin-Runt-related transcription factor 2 signaling. J Am Heart Assoc. 7(e007405)2018.PubMed/NCBI View Article : Google Scholar
36	Deng L, Huang L, Sun Y, Heath JM, Wu H and Chen Y: Inhibition of FOXO1/3 promotes vascular calcification. Arterioscler Thromb Vasc Biol. 35:175–183. 2015.PubMed/NCBI View Article : Google Scholar